Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Net Margin (2016 - 2026)

Collegium Pharmaceutical has reported Net Margin over the past 10 years, most recently at 8.26% for Q4 2025.

  • For Q4 2025, Net Margin rose 137.0% year-over-year to 8.26%; the TTM value through Dec 2025 reached 8.05%, down 636.0%, while the annual FY2025 figure was 8.05%, 290.0% down from the prior year.
  • Net Margin for Q4 2025 was 8.26% at Collegium Pharmaceutical, down from 15.05% in the prior quarter.
  • Over five years, Net Margin peaked at 117.26% in Q3 2024 and troughed at 359.53% in Q1 2022.
  • A 5-year average of 4.69% and a median of 8.93% in 2023 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: plummeted -37871bps in 2022 and later soared 34750bps in 2023.
  • Year by year, Net Margin stood at 65.31% in 2021, then skyrocketed by 91bps to 5.55% in 2022, then surged by 484bps to 21.33% in 2023, then crashed by -68bps to 6.89% in 2024, then increased by 20bps to 8.26% in 2025.
  • Business Quant data shows Net Margin for COLL at 8.26% in Q4 2025, 15.05% in Q3 2025, and 6.37% in Q2 2025.